- Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
- Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
- Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arvinas to Present at Upcoming Investor Conferences
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
On Tuesday, Arvinas Inc (ARVN:NSQ) closed at 35.25, -33.59% below its 52-week high of 53.08, set on Feb 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.31 |
---|---|
High | 36.20 |
Low | 34.50 |
Bid | 34.12 |
Offer | 37.48 |
Previous close | 35.25 |
Average volume | 793.62k |
---|---|
Shares outstanding | 68.43m |
Free float | 62.38m |
P/E (TTM) | -- |
Market cap | 2.41bn USD |
EPS (TTM) | -6.05 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼